Literature DB >> 3689205

Long-term effects of verapamil on aortic smooth muscle cells cultured in the presence of hypercholesterolemic serum.

O Stein1, G Halperin, Y Stein.   

Abstract

Smooth muscle cells derived from rabbit and bovine aorta were cultured for up to 5 weeks in the presence of d less than 1.019 g/ml fraction of hypercholesterolemic rabbit serum. When this fraction was added to serum containing culture medium, there was a significant increase in DNA, protein, and cholesteryl ester per dish. Addition of 50 microM verapamil markedly reduced the stimulatory effect of the d less than 1.019 g/ml fraction on both DNA and protein content per dish. The effect of verapamil on cholesteryl ester content was more complex: there was an increase within the first week, but later the net accumulation of cholesteryl ester per dish was lower than in untreated dishes. The recovery of less DNA in verapamil-treated dishes was not due to increased cell loss, as evidenced by retention of a residualizing marker, 3H-cholesteryl linoleyl ether. Moreover, verapamil did reduce incorporation of 3H-thymidine into DNA. In verapamil-treated dishes, there was flattening and a cobblestone appearance of the cells. A hypothesis is proposed to explain the inhibitory effect of verapamil on the development of atheroma formation in cholesterol-fed rabbits: Assuming that macrophages play an active role in cholesteryl ester removal from atheroma, verapamil, which reduces lysosomal cholesteryl ester hydrolysis in macrophages, would permit the lipid-laden macrophage to remove more cholesteryl ester per cell from the arterial wall. In addition, the presently reported results support the possibility that verapamil may impede the development of atheroma formation by reduction of smooth muscle cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689205     DOI: 10.1161/01.atv.7.6.585

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  12 in total

Review 1.  Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Authors:  P D Henry
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

3.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 4.  Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention.

Authors:  L G Spagnoli; A Mauriello; A Orlandi; G Sangiorgi; E Bonanno
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 5.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

6.  Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment.

Authors:  M N el-Sanadiki; K S Cross; J J Murray; R W Schuman; E Mikat; R L McCann; P O Hagen
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

Review 7.  Coadministration of calcium antagonists and ACE inhibitors--is a skeptic convinced?: a personal view.

Authors:  R W Campbell
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

8.  Cholesterol enrichment increases basal and agonist-stimulated calcium influx in rat vascular smooth muscle cells.

Authors:  R A Bialecki; T N Tulenko; W S Colucci
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

9.  Effect of platelet-derived growth factor on voltage-operated calcium channels in rabbit isolated ear artery cells.

Authors:  S Wijetunge; A D Hughes
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

10.  Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis.

Authors:  E Hoberg; R Dietz; U Frees; H A Katus; B Rauch; A Schömig; G Schuler; F Schwarz; H Tillmanns; J Niebauer
Journal:  Br Heart J       Date:  1994-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.